APA (7th ed.) Citation

Herrington, W. G., Preiss, D., Haynes, R., Eynatten, M. v., Staplin, N., Hauske, S. J., . . . Wanner, C. (2020). The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: A rationale for the EMPA-KIDNEY study. Clinical Kidney Journal, 13(4), 722. https://doi.org/10.1093/ckj/sfz009

Chicago Style (17th ed.) Citation

Herrington, William G., et al. "The Potential for Improving Cardio-renal Outcomes by Sodium-glucose Co-transporter-2 Inhibition in People with Chronic Kidney Disease: A Rationale for the EMPA-KIDNEY Study." Clinical Kidney Journal 13, no. 4 (2020): 722. https://doi.org/10.1093/ckj/sfz009.

MLA (9th ed.) Citation

Herrington, William G., et al. "The Potential for Improving Cardio-renal Outcomes by Sodium-glucose Co-transporter-2 Inhibition in People with Chronic Kidney Disease: A Rationale for the EMPA-KIDNEY Study." Clinical Kidney Journal, vol. 13, no. 4, 2020, p. 722, https://doi.org/10.1093/ckj/sfz009.